Can-Fite BioPharma Ltd. has reported promising results from its Phase IIa clinical study of namodenoson, a treatment for advanced pancreatic cancer. The announcement was made on October 26, 2026, during the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. This development is significant as it may enhance Can-Fite's position in the competitive pharmaceutical preparations industry.
Namodenoson is an orally administered drug that targets the A3 adenosine receptor, which is prevalent in tumor and inflammatory cells. The study achieved its primary safety endpoint, indicating that the drug was well tolerated among patients who had previously undergone systemic therapies.
According to the press release, the study enrolled 20 patients who received namodenoson at a dosage of 25 mg twice daily. Notably, one second-line patient achieved a progression-free survival of 16.39 months and an overall survival exceeding 20.7 months. The findings suggest that namodenoson may provide a viable treatment option for patients with advanced pancreatic ductal adenocarcinoma.
Background
Can-Fite BioPharma Ltd. is a biotechnology company focused on developing small molecule therapeutics for cancer and inflammatory diseases. The company is publicly traded on the NYSE under the ticker CANF. Can-Fite's lead drug candidate, Piclidenoson, is currently in a Phase 3 trial for psoriasis, while namodenoson is being evaluated for various cancers, including advanced liver cancer and pancreatic cancer.
What the Filing Says
The recent filing states, "The study achieved its primary safety endpoint, demonstrating that oral namodenoson was well tolerated in patients with advanced pancreatic cancer who had received prior systemic therapies." Additionally, exploratory analyses indicated encouraging survival outcomes, supporting further clinical development.
Impact
The positive results from the Phase IIa study may have significant implications for Can-Fite BioPharma, potentially increasing investor confidence and positioning the company favorably within the pharmaceutical preparations sector. The findings may also impact other companies developing treatments for pancreatic cancer, as they highlight the potential of namodenoson as a competitive option.
What's Next
The filing does not specify what happens next regarding the clinical development of namodenoson. However, the encouraging data presented at ESMO 2026 suggests that Can-Fite may pursue further clinical trials to explore the drug's efficacy in larger populations.